Ligand Pharmaceuticals Incorporated reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 28.1 million compared to USD 50.38 million a year ago. Net income was USD 18.19 million compared to net loss of USD 17.49 million a year ago. Basic earnings per share from continuing operations was USD 1.04 compared to basic loss per share from continuing operations of USD 0.86 a year ago. Diluted earnings per share from continuing operations was USD 1.03 compared to diluted loss per share from continuing operations of USD 0.86 a year ago. Basic earnings per share was USD 1.04 compared to basic loss per share of USD 1.04 a year ago. Diluted earnings per share was USD 1.03 compared to diluted loss per share of USD 1.04 a year ago.
For the full year, revenue was USD 131.31 million compared to USD 196.25 million a year ago. Net income was USD 52.15 million compared to net loss of USD 33.36 million a year ago. Basic earnings per share from continuing operations was USD 3.11 compared to basic loss per share from continuing operations of USD 0.31 a year ago. Diluted earnings per share from continuing operations was USD 3.03 compared to diluted loss per share from continuing operations of USD 0.31 a year ago. Basic earnings per share was USD 3.02 compared to basic loss per share of USD 1.98 a year ago. Diluted earnings per share was USD 2.94 compared to diluted loss per share of USD 1.98 a year ago.